Published • loading... • Updated
Viridian Therapeutics’ Stock up 35% After Phase III TED Data Release
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Viridian Therapeutics’ stock up 35% after Phase III TED data release
Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials.The post Viridian Therapeutics’ stock up 35% after Phase III TED data release appeared first on Clinical Trials Arena.
Viridian Therapeutics Reports Positive Phase 3 Results for Thyroid Eye Disease Drug
Key Takeaways Elegrobart significantly improved key symptoms of chronic thyroid eye disease in a phase 3 trial, with responder rates exceeding placebo The treatment was generally well tolerated and offers a more convenient at-home injection option compared to existing therapies. Viridian plans to seek FDA approval in early 2027 Viridian Therapeutics announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patie…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
